The association between HALP score and survival in patients treated with immune checkpoint inhibitors
Expert Review of Anticancer Therapy,
Год журнала:
2025,
Номер
unknown, С. 1 - 9
Опубликована: Янв. 7, 2025
Background
The
hemoglobin,
albumin,
lymphocyte,
and
platelet
(HALP)
score
could
be
a
prognostic
biomarker
in
patients
with
cancer
as
reflector
of
nutritional
inflammatory
status,
although
the
data
is
limited
treated
immune-checkpoint
inhibitors
(ICIs).
Therefore,
we
sought
to
investigate
relationship
between
HALP
survival
ICI-treated
patients.
Язык: Английский
Long-Term Toxicity of Immune Checkpoint Inhibitors—Time to Widen the Lens
JAMA Oncology,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 27, 2025
This
Viewpoint
discusses
the
need
to
quantify
long-term
adverse
effects
of
immune
checkpoint
inhibitors,
particularly
immune-related
effects,
which
are
not
universally
dose
dependent,
limiting
value
conventional
event
grading
systems.
Язык: Английский
Fear of Cancer Recurrence and Associated Factors in Lymphoma Survivors and Their Family Caregivers: A Cross‐Sectional Study
Cancer Medicine,
Год журнала:
2025,
Номер
14(7)
Опубликована: Март 29, 2025
ABSTRACT
Background
Fear
of
cancer
recurrence
(FCR)
is
a
pervasive
concern
among
lymphoma
survivors
and
their
family
caregivers,
influencing
psychological
physical
health.
Given
the
substantial
burden
FCR,
identifying
its
predictors
crucial
for
targeted
interventions
that
could
enhance
palliative
care.
We
aimed
to
evaluate
prevalence
FCR
in
as
well
associated
factors
Methods
A
total
118
patients
with
lymphoma,
along
were
recruited
from
Hacettepe
University
Cancer
Institute
between
March
2024
May
2024.
Psychological
assessments
conducted
using
Depression
Anxiety
Stress
Scales
(DASS‐21),
Recurrence
Inventory‐Short
Form
(FCRI‐SF)
Functional
Assessment
Therapy‐Lymphoma
(FACT‐Lym)
Results
High
levels
experienced
by
50.8%
(
n
=
60)
57.6%
68)
caregivers.
There
was
positive
correlation
caregivers
r
0.349,
p
<
0.001).
Poor
overall
quality
life
(QoL)
(aOR:
4.279,
95%
CI:
1.738–10.531,
0.002),
recent
diagnosis
(<
3
year)
5.135,
1.852–14.238,
survivors'
anxiety
2.540,
1.014–6.363,
0.002)
caregivers'
2.970,
1.119–7.879,
0.029)
high
survivors.
Conclusion
observed
over
half
higher
risk
anxiety,
poor
QoL
caregiver
FCR.
These
findings
highlight
critical
need
developing
comprehensive
care
plans
targeting
lymphoma.
Язык: Английский
Evaluating the clinical benefit of pembrolizumab as a first-line agent in advanced solid tumors: A comprehensive review
Journal of Oncology Pharmacy Practice,
Год журнала:
2024,
Номер
unknown
Опубликована: Май 6, 2024
Introduction
The
study
evaluates
the
first-line
application
of
pembrolizumab
in
metastatic
non-small-cell
lung
cancer
(mNSCLC),
head
and
neck
squamous
cell
(HNSCC),
gastric
cancer,
renal
carcinoma.
Utilizing
European
Society
for
Medical
Oncology
Magnitude
Clinical
Benefit
Scale
(ESMO-MCBS)
American
Value
Framework
(ASCO-VF),
analysis
incorporates
data
from
pivotal
KEYNOTE
trials.
Methods
systematically
assessed
clinical
benefit
advanced
solid
malignancies
through
nine
randomized
controlled
trials,
one
which
comprised
two
experimental
arms.
Data
extraction
primary
sources
was
conducted
PubMed,
ASCO,
ESMO
publications.
ESMO-MCBS
ASCO-VF
forms,
evaluation
focused
on
benefit,
toxicity,
bonus
points,
with
discrepancies
resolved
consensus
discussions.
Results
Nine
indications
received
Food
Drug
Administration
approval
tumors
between
2018
2023.
Notable
distinctions
grades
revealed
seven
trials
substantial
(grades
5
to
4)
three
moderate
negligible
3
1).
Bonus
primarily
based
tail
curve,
were
allocated
overall
survival,
progression-free
a
significant
improvement
quality
life.
Conclusions
Our
across
diverse
cancers,
especially
mNSCLC
HNSCC,
varied
outcomes
challenges
interpretation.
assessment
incorporating
quantitative
qualitative
endpoints,
underscores
need
consider
survivorship
patient
perspectives
comprehensive
understanding.
Язык: Английский
Outpatient psychosocial screening in a skin cancer center: acceptance, psychosocial distress and utilization of support
Deleted Journal,
Год журнала:
2024,
Номер
unknown
Опубликована: Май 8, 2024
Zusammenfassung
Hintergrund
Die
psychosoziale
Versorgung
von
Krebspatienten
nimmt
über
den
gesamten
Verlauf
der
onkologischen
Behandlung
einen
wichtigen
Stellenwert
ein.
Seit
2015
ist
das
Screening
in
Ambulanzen
des
Hauttumorzentrums
Freiburg
implementiert.
Wir
präsentieren
hier
eine
Post-hoc-Analyse
im
Rahmen
Qualitätssicherung.
Fragestellung
Akzeptanz,
Belastung
und
Inanspruchnahme
wurden
evaluiert.
Explorativ
untersuchten
wir,
welche
Patienten-
Krankheitsmerkmale
mit
einer
erhöhten
subjektiven
zusammenhängen.
Material
Methoden
In
Vollerhebung
06/2015
bis
12/2015
die
mittels
Distress-Thermometer
(DT)
Beratungswunsch
ausgewertet.
Ergebnisse
Von
753
Patienten
haben
345
(45,8
%)
am
psychosozialen
teilgenommen
Daten
310
(m:w
174:136;
89,7
%
Melanompatienten,
mittlere
Zeit
seit
Erstdiagnose
4,7
±
3,9
Jahre)
konnten
ausgewertet
werden.
auf
dem
DT
betrug
2,97
2,83
(Median
2,
Range
0
10).
Eine
überschwellige
(DT
≥
5)
wurde
84
(28,8
angegeben;
34
(11
gaben
an,
23
nahmen
Beratungsangebot
Anspruch.
überschwelliger
waren
jünger,
befanden
sich
häufiger
unter
laufender
oder
kürzlich
abgeschlossener
medikamentöser
Therapie
hatten
Beratungswunsch.
Diskussion
Neben
Erhebung
validierten
Screeninginstrumenten
stellt
Betreuungswunsches
Parameter
zur
Identifikation
betreuungsbedürftigen
dar.
Junge
Systemtherapie
sollten
Fokus
Aufmerksamkeit
rücken.